

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/600 868
		Filing Date	12/22/2000
Date Submitted:		First Named Inventor	Ken Lipson
		Group Art Unit	1614
(use as many sheets as necessary)		Examiner Name	SPIVACK
		Attorney Docket Number	038602-0994
Sheet	1	of	30

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS	B1	Re. 35,096	E	Taniguchi et al.	11-21-1995	
PS	B2	Re. 36,256	E	Spada et al.	07-20-1999	
PS	B3	2,622,980		Copeland	12-23-1952	
PS	B4	2,872,372		Hull	02-03-1959	RECEIVED SEP 06 2002
PS	B5	2,968,557		Burgandt et al.	01-17-1961	
PS	B6	3,140,180		Fritz	07-07-1964	TECH CENTER 1600/2900
PS	B7	3,308,134		Plostneiks	03-07-1967	
PS	B8	3,551,571		Pachter et al.	12-29-1970	
PS	B9	3,564,016		Schoen et al.	02-16-1971	
PS	B10	3,715,364		Hoff	02-06-1973	
PS	B11	3,880,871		Haugwitz et al.	04-29-1975	
PS	B12	3,922,163		Church et al.	11-25-1975	
PS	B13	4,002,643		Carson	01-11-1977	
PS	B14	4,002,749		Rovnyak	01-11-1977	
PS	B15	4,053,613		Rovnyak et al.	10-11-1977	
PS	B16	4,070,366		Gregorovich et al.	01-24-1978	
PS	B17	4,259,345		Cross et al.	03-31-1981	
PS	B18	4,343,923		Lenox et al.	08-10-1982	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	
Sheet	2	of	30		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS	B19	4,376,110		David et al.	03-08-1983	
PS	B20	4,436,892		Zondler et al.	03-13-1984	
PS	B21	4,489,089		Wright, Jr. et al.	12-18-1984	
PS	B22	4,493,642		Furazawa et al.	01-15-1985	
PS	B23	4,628,105		Schmid et al.	12-09-1986	
PS	B24	4,642,309		Michel et al.	02-10-1987	
PS	B25	4,826,847		Michel et al.	05-02-1989	
PS	B26	4,853,403		Shiraishi et al.	08-01-1989	
PS	B27	4,853,404		Takamura et al.	08-01-1989	
PS	B28	4,868,304		Larock	09-19-1989	
PS	B29	4,924,000		Rentzea et al.	05-08-1990	
PS	B30	4,966,849		Vallee et al.	10-30-1990	
PS	B31	4,971,996		Shiraishi et al.	11-20-1990	
PS	B32	4,987,146		Rohde et al.	01-22-1991	
PS	B33	5,043,348		Zoller et al.	08-27-1991	
PS	B34	5,043,454		Wriede et al.	08-27-1991	
PS	B35	5,047,554		Ehrgott et al.	09-10-1991	
PS	B36	5,051,417		Nadler et al.	09-24-1991	

Examiner Signature		Date Considered	1/23/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	 12/22/2000 Ken Lipson 1614  038602-0994
Sheet	3	of	30

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS	B37	5,057,538		Shiraishi et al.	10-15-1991	
PS	B38	5,082,856	A	Taniguchi et al.	01-21-1992	
PS	B39	5,089,516	A	Shiraishi et al.	02-18-1992	
PS	B40	5,124,347	A	Connor et al.	06-23-1992	
PS	B41	5,145,983	A	West	09-08-1992	
PS	B42	5,153,217	A	Taniguchi et al.	10-06-1992	
PS	B43	5,196,446	A	Levitzki et al.	03-23-1993	
PS	B44	5,202,341	A	Shiraishi et al.	04-13-1993	
PS	B45	5,206,261	A	Kawaguchi et al.	04-27-1993	
PS	B46	5,217,999	A	Levitzki et al.	06-08-1993	
PS	B47	5,258,357	A	Muenster et al.	11-02-1993	
PS	B48	5,278,184	A	Artico et al.	01-11-1994	
PS	B49	5,290,947	A	Zoller et al.	03-01-1994	
PS	B50	5,302,606	A	Spada et al.	04-12-1994	
PS	B51	5,322,950	A	Sircar et al.	06-21-1994	
PS	B52	5,330,992	A	Eissenstat et al.	07-19-1994	
PS	B53	5,332,736	A	Carmosin et al.	07-26-1994	
PS	B54	5,374,652	A	Buzzetti et al.	12-20-1994	

Examiner Signature	Phyllis Sawick	Date Considered	1/23/05
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				Filing Date	
Date Submitted:				First Named Inventor	
				Group Art Unit	
(use as many sheets as necessary)				Examiner Name	
				Attorney Docket Number	
Sheet	4	of	30		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS	B55	5,382,593	A	Le Baut et al.	01-17-1995	
PS	B56	5,389,661	A	Sircar et al.	02-14-1995	
PS	B57	5,397,787	A	Buzzetti et al.	03-14-1995	
PS	B58	5,409,930	A	Spada et al.	04-25-1995	
PS	B59	5,409,949	A	Buzzetti et al.	04-25-1995	
PS	B60	5,463,052	A	Haga et al.	10-31-1995	
PS	B61	5,565,324	A	Still et al.	10-15-1996	
PS	B62	5,610,173	A	Schwartz et al.	03-11-1997	
PS	B63	5,723,665	A	Kato et al.	03-03-1998	
PS	B64	5,786,488	A	Tang et al.	07-28-1998	
PS	B65	5,792,783	A	Tang et al.	08-11-1998	
PS	B66	5,834,504	A	Tang et al.	11-10-1998	
PS	B67	5,849,710	A	Battistini et al.	12-15-1998	
PS	B68	5,880,141	A	Tang et al.	03-09-1999	
PS	B69	5,883,113	A	Tang et al.	03-16-1999	
PS	B70	5,883,116	A	Tang et al.	03-16-1999	

Examiner Signature	<i>Phillis Spinack</i>	Date Considered	1/23/05
-----------------------	------------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
Sheet	5	of	30	Application Number	
				Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	1614
				Examiner Name	
				Attorney Docket Number	038602-0994

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS	B71	5,886,020	A	Tang et al.	03-23-1999	
PS	B72	6,130,239	A	Chen et al.	10-10-2000	
PS	B73	6,133,305	A	Tang et al.	10-17-2000	
PS	B74	6,284,894	B1	Phillion et al.	09-04-2001	
PS	B75	6,310,217	B1	Lehr	10-30-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS	B76	WO	88/07035	A1	KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA	09-22-1988		
PS	B77	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991		
PS	B78	WO	91/15495	A1	PFIZER INC.	10-17-1991		
PS	B79	WO	92/03736	A1	SEIKAGAKU KOGYO KABUSHIKI KAISHA	03-05-1992		
PS	B80	WO	92/07830	A2	PFIZER INC.	05-14-1992		
PS	B81	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		
PS	B82	WO	92/21660	A1	PFIZER INC.	12-10-1992		
PS	B83	WO	93/01182	A1	FARMITALIA CARLO ERA SRL	01-21-1993		

Examiner Signature	<i>Phillip Spivack</i>	Date Considered	1/23/05
--------------------	------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet 6 of 30				Attorney Docket Number 038602-0994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS	B84	WO	93/23040	A1	MERCK & CO., INC.	11-25-1993		
PS	B85	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
PS	B86	WO	94/10202	A1	GENENTECH, INC.	05-11-1994		
PS	B87	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994		
PS	B88	WO	95/01349	A1	FARMITALIA CARLO ERBA SRL	01-12-1995		
PS	B89	WO	95/14667	A1	PFIZER INC.	06-01-1995		
PS	B90	WO	95/17181	A1	PHARMACIA S.P.A.	06-29-1995		
PS	B91	WO	95/24190	A2	SUGEN, INC.	09-14-1995		
PS	B92	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996		
PS	B93	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996		
PS	B94	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996		
PS	B95	WO	96/32380	A1	PHARMACIA S.P.A.	10-17-1996		
PS	B96	WO	96/40116	A1	SUGEN, INC.	12-19-1996		
PS	B97	WO	97/25986	A1	TAIHO PHARMACEUTICAL CO., LTD.	07-24-1997		
PS	B98	WO	97/34920	A1	SUGEN, INC.	09-25-1997		
PS	B99	WO	97/36867	A1	PFIZER, INC.	10-09-1997		
PS	100	WO	98/07695	A1	SUGEN, INC.	02-26-1998		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet <u>7</u> of <u>30</u>				Attorney Docket Number <u>038602-0994</u>	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS	101	WO	98/07835	A2	SUGEN, INC.	02-26-1998		
PS	102	WO	98/24432	A2	SUGEN, INC.	06-11-1998		
PS	103	WO	98/38984	A2	SUGEN, INC.	09-11-1998		
PS	104	WO	98/45708	A1	SUGEN, INC.	10-15-1998		
PS	105	WO	98/50356	A1	SUGEN, INC.	11-12-1998		
PS	106	WO	98/56376	A1	SUGEN, INC.	12-17-1998		
PS	107	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999		
PS	108	WO	99/19325	A1	SYNTHELABO	04-22-1999		
PS	109	WO	99/48868	A2	SUGEN, INC.	09-30-1999		
	110	WO	99/52869	A1	BOEHRINGER INGELHEIM PHARMA KG	10-21-1999		
PS	111	WO	99/65869	A1	BAYER AKTIENGESELLSCHAFT	12-23-1999		
PS	112	WO	99/61422	A1	SUGEN, INC.	12-02-1999		
PS	113	WO	00/38519	A1	SUGEN, INC.	07-06-2000		
	114	WO	00/08202	A2	SUGEN, INC.	02-17-2000		
PS	115	WO	00/56709	A1	SUGEN, INC.	09-28-2000		
PS	116	WO	01/60814	A2	SUGEN, INC.	08-23-2001		
PS	117	DE	878,539		Von FREYBERG, et al.	06-05-1953		X
PS	118	DE	2,159,360	A	BAYER AG	06-14-1973		X

Examiner Signature	Date Considered	
Phyllis Spivack	1/23/05	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet <u>8</u> of <u>30</u>				Attorney Docket Number <u>038602-0994</u>	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS	119	DE	2,159,361	A	BAYER AG	06-14-1973		X
PS	120	DE	2,159,362		BAYER AG	06-14-1973		
PS	121	DE	2,159,363	A	BAYER AG	06-14-1973		X
PS	122	DE	2,321,656	A	COLGATE-PALMOLIVE CO.	11-15-1973		X
PS	123	DE	3,426,419	A	BOEHRINGER MANNHEIM GMBH	01-23-1986		X
PS	124	EP	0 252 713	B1	PFIZER INC.	01-13-1988		
PS	125	EP	0 304 493	B1	KANEGAFUCHI KAGAKU KOGTO KABUSHIKI KAISHA	03-01-1989		
PS	126	EP	0 351 213	A2	LES LABORATOIRES BEECHAM S.A.	01-17-1990		
PS	127	EP	0 525 472	A2	FARMITALIA CARLO ERBA SRL	02-03-1993		
PS	128	EP	0 566 226	B1	ZENECA LIMITED	10-20-1993		
PS	129	EP	0 580 502	B1	ADIR ET COMPAGNIE	01-26-1994		X
PS	130	EP	0 626 377	B1	SHIONOGI & CO., LTD.	11-30-1994		
PS	131	EP	0 632 102	A1	BAYER AG	01-04-1995		X
PS	132	EP	0 662 473	A1	PHARMACIA S.P.A.	07-12-1995		
PS	133	EP	0 788 890	A1	AGFA-GEVAERT	08-13-1997		
PS	134	EP	0 810 217	A1	JAPAN ENERGY CORPORATION	12-03-1997		
PS	135	EP	0 769 947	B1	TANG, Peng Cho et al.	05-02-1997		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet 9 of 30				Attorney Docket Number 038602-0994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS	136	EP	0 934 931	A2	SUGEN, INC.	08-11-1999		
PS	137	EP	1 082 305	A1	SUGEN, INC.	03-14-2001		
PS	138	FR	1.398.224		IMPERIAL CHEMICAL INDUSTRIES LIMITED	05-07-1965		X
PS	139	FR	1.599.772		INSTITUT PASTEUR	08-28-1970		X
PS	140	FR	2.689.397	A1	ADIR ET COMPAGNIE	10-08-1993		X
PS	141	GB	809,691		Roy HULL	03-04-1959		
PS	142	GB	835,473		Norman SENIOR	05-18-1960		
PS	143	JP	62-29570	A	KANEGAFUCHI CHEM KK	02-07-1987		X
PS	144	JP	62-39564	A	KANEGAFUCHI CHEM KK	02-20-1987		X
PS	145	JP	63-141955	A	KANEGAFUCHI CHEM KK	06-14-1988		X
PS	146	JP	5-58894	A	KANEKA CORP	03-09-1993		X
PS	147	CA	2,012,634	A1	UNIVERSITY OF BRITISH COLUMBIA	09-20-1991		
PS	148	AU	286870		IMPERIAL CHEMICAL INDUSTRIES OF AUSTRALIA AND NEW ZEALAND LIMITED	05-11-1967		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number Filing Date 12/22/2000 First Named Inventor Ken Lipson Group Art Unit 1614 Examiner Name Attorney Docket Number 038602-0994	
Sheet	10	of	30		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
PS	B149	ABRAMOVITCH and HEY, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," <u>J. Chem. Soc.</u> 1697-1703 (1954), Strand, London		
PS	B150	ABRAMOVITCH et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," <u>Chemistry and Industry</u> 44:1871 (1967) ©Laporte Industries Limited, Lancashire		
	B151	<del>Beilstein Reg. No. 236050, Beilstein Reference No. 4-21-00-06355</del>		
PS	B152	AKBASAK and SUNAR-AKBASAK, "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992) © Elsevier Science Publishers		
PS	B153	ANDREANI et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones," <u>Anticancer Research</u> 16:3585-3588 (1996) © Elsevier, Paris		
PS	B154	ANDREANI et al., "Synthesis and cardiotoxic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)		
PS	B155	ANDREANI et al., "Synthesis and cardiotoxic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993) © Elsevier, Paris		
PS	B156	ANDREANI et al., "Synthesis and cardiotoxic activity of 2-indolinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 78106 (1990)		
PS	B157	ANDREANI et al., "Synthesis and cardiotoxic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992) © Elsevier, Paris		
PS	B158	ANDREANI et al., "Synthesis and potential coanthracyclic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997) © Elsevier, Paris		
PS	B159	ANDREANI et al., "Synthesis of lactams with potential cardiotoxic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number Filing Date 12/22/2000 First Named Inventor Ken Lipson Group Art Unit 1614 Examiner Name Attorney Docket Number 038602-0994	
Sheet	11	of	30		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exami ner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
E	B160	ANDREANI et al., "In Vivo Cardiotoxic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48:727-729 (1998) *		
PS	B161	ARTEAGA et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.		
PS	B162	ARVIDSSON et al., "Tyr-716 in the Platelet-Derived Growth Factor $\beta$ -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994) * The American Society for Microbiology		
PS	B163	AUTREY and TAHK, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967) *Pergamon Press		
PS	B164	BAHNER and BROTHERTON, "9-(4-Aminobenzylidene)fluorenes," <u>J. Med. Chem.</u> 12:722-723 (1969)		
PS	B165	BAHNER et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>J. Med. Chem.</u> 12:721-722 (1969)		
PS	B166	BAMFIELD et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> 1028-1030 (1966) *		
PS	B167	BARBIER, et al., "Synthesis of Isobrassilexin, A Biologically Active Isomer of Brassilexin, a Cruciferae Phytoalexin," <u>Synthetic Communications</u> 23(22):3109-3117 (1993) * Marcel Dekker, Inc.		
PS	B168	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994) * Cell Press		

Examiner Signature	<i>Phillip Spivack</i>	Date Considered	11/23/05
-----------------------	------------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	12	of	30	Attorney Docket Number	
				038602-0994	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exami ner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
Ps	B169	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)		
Ps	B170	Beilstein Reg. No. 233511 (1997)		
Ps	B171	Beilstein Reg. No. 235647 (1997)		
Ps	B172	Beilstein Reg. No. 252929 (1998)		
Ps	B173	BENZIES, et al., "2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole," <u>Synthetic Communications</u> : 16(14), 1799-1807 (1986) © Mercei Dekker, Inc.		
Ps	B174	BLAKE and JAUQUES, "Anisotropic Effects in $\alpha$ -Substituted Methoxystilbenes," <u>J. Chem. Soc. Perkin II</u> : 1660-1663 (1973) © Pergamon, Oxford		
Ps	B175	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)		
Ps	B176	BOLEN, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993) copyright MacMillan Press Ltd.		
Ps	B177	BONNER et al., "Structure and Biological Activity of Human Homologs of the <i>raf/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985) © The American Society for Microbiology		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
-----------------------	-----------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		<b>Application Number</b>	
		<b>Filing Date</b>	12/22/2000
		<b>First Named Inventor</b>	Ken Lipson
		<b>Group Art Unit</b>	1614
		<b>Examiner Name</b>	
<b>Sheet</b>	13	<b>of</b>	30
		<b>Attorney Docket Number</b>	038602-0994

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B178	BORSCHÉ et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)	
PS	B179	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)	
PS	B180	CANCE et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993) © Wiley-Liss, Inc.	
PS	B181	CANOIRA and RODRIGUEZ, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>J. Heterocyclic Chem.</u> 22:1511-1518 (1985)	
PS	B182	CARPENEDO et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997) © Academic Press, Inc.	
PS	B183	CHAO, "Growth Factor Signaling: Where Is the Specificity?" <u>Cell</u> 68:995-997 (1992) copyright Cell Press	
PS	B184	CHATTEN et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted <i>trans</i> -3-Benzylideneindol-2(3 <i>H</i> )-ones," <u>J. Chem. Soc. Perkin II</u> : 469-473 (1973)	
PS	B185	CHATTERJEE, et al., "Acylation of Indoles by Duff Reaction and Vilsmeier-Haack Formylation and Conformation of N-Formylindoles," <u>J. Org. Chem.</u> , 38:4002-4004 ©The American Chemical Society	
PS	B186	CHEN et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on $\gamma$ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40:149-156 (1997)	

<b>Examiner Signature</b>	Phyllis Spivack	<b>Date Considered</b>	1/23/05
---------------------------	-----------------	------------------------	---------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	14	of	30	Attorney Docket Number	
				038602-0994	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
PS	B187	CLAESSION-WELSH, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994) © Elsevier Science Ltd.		
PS	B188	CODA et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin Trans. II</u> : 615-619 (1984)		
PS	B189	CODA et al., "3-(4-methylbenzylidene)-1,3-dihydroindol-2-one," <u>Journal of the Chemical Society, Perkin Transactions 2</u> 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21		
PS	B190	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994) © The American Society for Microbiology		
PS	B191	DAISLEY and WALKER, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," <u>J. Chromatography</u> 100:240-242 (1974) © Elsevier Scientific Publishing Company		
PS	B192	DAMIANI et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48:1155-1161 (1994) copyright Elsevier Science Ltd.		
PS	B193	DATI et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)		
PS	B194	DAVIS et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16:1043-1045 (1973) © American Chemical Society		
PS	B195	DE VRIES et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		Application Number	
		Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	1614
		Examiner Name	
Sheet	15	of	30
		Attorney Docket Number	038602-0994

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B196	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988) copyright Elsevier	
PS	B197	DECODTS et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," <u>Eur. J. Med. Chem</u> 18: 107-111 (1983)	
PS	B198	DESIMONI et al., "Catalysis with Inorganic Cations. V <sup>1</sup> Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity," <u>Tetrahedron</u> 52(36) 12009-12018 (1196) © Pergamon	
PS	B199	DICKSON et al., "13. Tyrosine kinase receptor - nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992) © Kluwer Academic Publishers	
PS	B200	ELLIOTT and RIVERS, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," <u>J. Med. Chem.</u> 29:2438-2440 (1964)	
PS	B201	ELLIOTT et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," <u>Journal of Organic Chemistry</u> 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24	
PS	B202	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992) © Cell Press	
PS	B203	FENDLY et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product," <u>Cancer Research</u> 50:1550-1558 (1990); @ American Association for Cancer Research	
B	B204	FERRARA and HENZEL, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989) © Academic Press, Inc.	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number: 03/741,300 Filing Date: 12/22/2000 First Named Inventor: Ken Lipson Group Art Unit: 1614 Examiner Name: [blank] Attorney Docket Number: 038602-0994	
Sheet	16	of	30		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
PS	B205	FINGL and WOODBURY, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) © MacMillan Publishing Co. Inc.		
PS	B206	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43:S47-S54 (1993) © International Society of Nephrology		
PS	B207	FLOEGE et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993) © International Society of Nephrology		
B	B208	FOLKMAN and SHING, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992) © The American Society for Biochemistry and Molecular Biology		
PS	B209	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)		
PS	B210	FOLKMAN, "Tumor Angiogenesis: Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)		
PS	B211	FOLKMAN, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)		
PS	B212	FOLKMAN, "Angiogenesis in Psoriasis: Therapeutic Implications," <u>J. Invest. Dermatol.</u> 59:40-43 (1973) copyright The Williams & Wilkins Co.		
B	B213	GAZIT et al., "Tyrphostins. 2. Heterocyclic and $\alpha$ -Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991) copyright Am. Chem. Soc.		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number Filing Date 12/22/2000 First Named Inventor Ken Lipson Group Art Unit 1614 Examiner Name Attorney Docket Number 038602-0994	
Sheet	17	of	30		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
B	B214	GENNARO (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)		
PS	B215	GOLDRING and GOLDRING, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)		
B	B216	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30:311-314 (1988) © Pergamon Press		
B	B217	GRAZIANI et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268:9165-9168 (1993) ©American Society for Biochemistry and Molecular Biology		
B	B218	HAYLER et al., Development of Large-Scale Syntheses of Ropinirole in the Pursuit if a Manufacturing Process," <u>Organic Process Research &amp; Development</u> 2(1) 3-9 (1998) ©The American Chemical Society and Royal Society of Chemistry		
B	B219	HEWGILL and STEWART, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," <u>J. Chem. Soc. Perkin Trans. I</u> :1305-1311 (1988)		
PS	B220	HIRAO et al., "Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones," <u>Tetrahedron Letters</u> 36(35) 1995 ©Pergamon		
PS	B221	HODGES et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)		
B	B222	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987) © Cell Press		

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	41002
		Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	1614
		Examiner Name	Reamer
Sheet	18	of	30
		Attorney Docket Number	036602-0994

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B223	<del>HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," J. Biol. Chem. 267:26031-26037 (1992) © American Society for Biochemistry and Molecular Biology, Inc.</del>	
	B224	HOWARD, Harry R., "Lactam Derivatives," U.S. Provisional Patent Application Number 60/015134	
PS	B225	HOWARD et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids," Eur. J. Med. Chem. 27:779-789 (1992) © Elsevier, Paris	
	B226	HU et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," Molecular and Cellular Biology 12:981-990 (1992) copyright Am. Soc. Microbiol.	
PS	B227	IJAZ et al., "The Conversion of $\alpha,\beta$ -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," J. Chem. Res. (S): 116 (1990)	
PS	B228	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994) © American Chemical Society	
PS	B229	KASHISHIAN and COOPER, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C $\gamma$ 1," Molecular Biology of the Cell 4:49-57 (1993) © The American Society for Cell Biology	
PS	B230	KASHISHIAN et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase <i>in vivo</i> ," The EMBO Journal 11:1373-1382 (1992)	
PS	B231	KATO et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," Journal of Chromatography 616:67-71 (1993) © Elsevier Science	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	
		Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	1614
		Examiner Name	
Sheet	19	of	30
		Attorney Docket Number	038602-0994

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B232	KATRITZKY et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs-Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)	
PS	B233	KAZLAUSKAS et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor $\beta$ subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)	
PS	B234	KENDALL and THOMAS, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)	
PS	B235	KHALIL and ABDEL-RAHMAN, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> 54:904-907 (1977) ©The Indian Chemical Society	
PS	B236	KIKUMOTO et al., "The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides," <u>Tetrahedron</u> 22: 3337-3343 (1966) ©Pergamon Press Ltd.	
PS	B237	KIM et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)	
PS	B238	KINSELLA et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992) © Academic Press, Inc.	
PS	B239	KLAGSBRUN and SOKER, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993) ©Current Biology	
PS	B240	KOBAYASHI et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97:1033-1039 (1977)	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number Filing Date 12/22/2000 First Named Inventor Ken Lipson Group Art Unit 1614 Examiner Name Attorney Docket Number 038602-0994	
Sheet	20	of	30		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
PS	B241	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)		
PS	B242	KOHLE and MILSTEIN, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975)		
PS	B243	KOMADA and KITAMURA, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)		
PS	B244	KORC et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.		
PS	B245	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983) © Elsevier Science Publishers		
PS	B246	KOVAC and STETINOVA, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles," <u>Chem. resu</u> 30:484-492 (1976)		
PS	B247	KRUEGER and SAITO, "A human transmembrane protein-tyrosine-phosphatase, PTPb, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> 89:7417-7421 (1992)		
PS	B248	KUMABE et al., "Amplification of $\alpha$ -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)		

Examiner Signature	Phyllis Spivaak	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		Application Number	
		Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	1614
		Examiner Name	J. Reamer
Sheet	21	of	30
		Attorney Docket Number	038602-0994

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B249	LAL et al., "Novel Diuretic Agents: Syntheses of Substituted Isatylidenes & 3-Alkyl or 3-Arylalkyl-2-oxindoles," <u>Indian Journal of Chemistry</u> 13: 898-903 (1975)	
PS	B250	LAROCK and BABU, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:5291-5294 (1987) copyright Pergamon Journals Ltd.	
PS	B251	LEE and DONOGHUE, "Intracellular Retention of Membrane-Anchored v-sis Protein Abrogates Autocrine Signal T transduction," <u>J. Cell. Biol.</u> 118:1057-1070 (1992) ©The Rockefeller University Press	
PS	B252	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995)	
PS	B253	MAASS et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37:2612-2617 (1993) ©American Society for Microbiology	
PS	B254	MACAULAY et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells," <u>Cancer Research</u> 50:2511-2517 (1990)	
PS	B255	MARIANI et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)	
PS	B256	MARTIN-LEON et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring Some New Facts," <u>Liebigs Ann. Chem.</u> 101-104 (1990) copyright VCH Verlagsgesellschaft mbH ©VCH	
PS	B257	MEL'NIKOVA TV et al., "Indole chemistry. XXXVIII. Cleavage of a carbon-carbon bond during the reaction of 2-aminoindoles with difunctional compounds," <u>Chemical Abstracts</u> 80 (1974) Abstract No. 003413	

Examiner  
Signature

Phyllis Spivack

Date  
Considered

1/23/05

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	37/113,000
		<b>Filing Date</b>	12/22/2000
		<b>First Named Inventor</b>	Ken Lipson
		<b>Group Art Unit</b>	1614
		<b>Examiner Name</b>	Rechner
Date Submitted: (use as many sheets as necessary)		<b>Attorney Docket Number</b>	038602-0994
Sheet	22	of	30

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B258	MILLAUER et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) © Cell Press	
PS	B259	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (1997) © American Association for the Advancement of Science	
PS	B260	MORETO et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DAN-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) ©North-Holland Publishing Company	
PS	B261	MORETO et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29:1561-1564 (1979)	
PS	B262	MORRISON et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988)	
PS	B263	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) copyright Elsevier Publishers B.V.	
PS	B264	NEBER and RÖCKER, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," <u>Chem. Ber.</u> 56:1710-1716 (1923) (GERMAN AND ENGLISH TRANSLATION)	
PS	B265	NISHIMURA et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)	
PS	B266	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>J. Med. Chem.</u> 14:921-925 (1971)	

Examiner Signature	Phyllis Spinack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	038602-0994 12/22/2000 Ken Lipson 1614 Permer 038602-0994
Sheet	23	of	30

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B267	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 83, abstract no. 188214 (1975)	
PS	B268	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)	
PS	B269	O'SULLIVAN and ROTHERY, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975) ©Elsevier Scientific Publishing Company	
PS	B270	OZZELLO and SORDAT, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)	
PS	B271	PAVLENKO et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr Rrsrs. Ser. B: Geol., Khim. Biol. Nauki</u> 7:64-66 (1980) We should add that we are Sub. Abstract	
PS	B272	PERKIN et al., "Harmine and Harmaline. Part II. The Synthesis of isoHarman," <u>J. Chem. Soc.</u> 103:1973-1985 (1913)	
PS	B273	PLATE et al., "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo," <u>Nature</u> 359:845-848 (1992)	
PS	B274	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&amp;P</u> 7:334-339 (1994)	
PS	B275	QUALLICH et al., A General Oxindole Synthesis," <u>J. Synthetic Organic Chemistry</u> : 51-51 (1993)	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	001112
		<b>Filing Date</b>	12/22/2000
		<b>First Named Inventor</b>	Ken Lipson
		<b>Group Art Unit</b>	1614
		<b>Examiner Name</b>	Rean
Date Submitted: (use as many sheets as necessary)		<b>Attorney Docket Number</b>	038602-0994
Sheet	24	of	30

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
B	B276	QUINN et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)	
B	B277	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)	
B	B278	RUVEDA and GONZALEZ, "Geometric isomerism in benzylideneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)	
B	B279	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta Path. Microbiol. Scand.</u> 77:758-760 (1969)	
Ps	B280	SAINSBURY et al., "Electrochemical Oxidation of Aromatic Ethers. Part 5. <sup>1</sup> Further Studies of the Coupling Reactions of Alkoxyated Aralkyl- and Aryl-amides," <u>J.C.S. Perkin I</u> 108-114	
Ps	B281	SAITO and STREULI, "Molecular Characterization of Protein Tyrosine Phosphatases," <u>Cell Growth &amp; Differentiation</u> 2:59-65 (1991) ©Molecular Biology Journal of the American Association for Cancer Research	
B	B282	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)	
Ps	B283	SCHINDLER et al., "Über Dibenz[b,f]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)	
B	B284	SCHLESSINGER and ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992) © Cell Press	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	US 2004/01942
		<b>Filing Date</b>	12/22/2000
Date Submitted:		<b>First Named Inventor</b>	Ken Lipson
		<b>Group Art Unit</b>	1614
(use as many sheets as necessary)		<b>Examiner Name</b>	J. P. [unclear]
Sheet	25	of	30
		<b>Attorney Docket Number</b>	038602-0994

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B285	SCHUCHTER et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," <u>Cancer Research</u> 51:682-687 (1991)	
PS	B286	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells <u>in Vitro</u> and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2234 (1983)	
PS	B287	SHAFIE and GRANTHAM, "Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67:51-56 (1981)	
PS	B288	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <u>Oncogene</u> 5:519-524 (1990)	
PS	B289	SHIRAISHI et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987)* Academic Press	
PS	B290	SHIRAISHI et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives <u>in Vitro</u> ," <u>Cancer Research</u> 49:2374-2378 (1989)	
PS	B291	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992)	
PS	B292	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena	
PS	B293	SINGH et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Date Submitted:				Attorney Docket Number	
(use as many sheets as necessary)					
Sheet	26	of	30		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B294	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)	
PS	B295	SLAMON et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)	
PS	B296	SOLDI et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 <sup>FAK</sup> ) in Human Endothelial Cells," <u>Oncogene</u> 13:515-525 (1996) copyright Stockton Press	
PS	B297	SONGYANG et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993) © Cell Press	
PS	B298	SONGYANG et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994) © American Society for Microbiology	
PS	B299	SPADA, et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5:805-817 (1995) ©Ashley Publications	
PS	B300	STETINOVA et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection Czechoslov. Chem. Commun.</u> 42:2201-2206 (1977)	
PS	B301	STOLLE, Beilstein Reg. No. 273650, <u>J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)	
PS	B302	STOLLE, Beilstein Reg. No. 305045, <u>J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)	

Examiner Signature	Phyllis Spivack	Date Considered	1/25/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)				Application Number	12/22/2000
				Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	1614
				Examiner Name	C. R. Zamer
Sheet	27	of	30	Attorney Docket Number	038602-0994

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B303	SUMPTER and MILLER, "Chapter IV - Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , © Interscience Publishers, Inc., New York, pp. 134-153 (1954)	
PS	B304	SUN et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidene]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," <u>Journal of Medicinal Chemistry</u> 42: 5120-5130 (1999) © American Chemical Society	
PS	B305	SUN et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998) © The American Chemical Society	
PS	B306	SUPERTI-FURGA et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech.</u> 14:600-605 (1996)	
PS	B307	SUPERTI-FURGA et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993) © Oxford University Press	
	B308	<del>TACCONI and MARINONE, "Preparazione e caratteristiche di alcuni 3-ossindolidendervati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)</del>	
PS	B309	TACCONI et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> 150-154 (1976)	
PS	B310	TAKANO et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits Protein Kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)	
PS	B311	TERRETT et al., "Combinatorial Synthesis - The Design of Compound Libraries and their Application to Drug Discovery," <u>Tetrahedron</u> 51(30):8135-8173 (1995) copyright Pergamon! all even pages missing!	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		Application Number	09/741,542
		Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	1614
		Examiner Name	J. Reames
		Attorney Docket Number	038602-0994
Sheet	28	of	30

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B312	THIO et al., "The Interconversion of 2-(2-Aminophenyl)-3-piperolidinone and 3-(2-piperidylmethyl)-2-indolinone: A Reversible N = N' Transacylation," <u>Notes</u> (1971) 479-482	
PS	B313	THOMPSON et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> 1835-1837 (1993)	
PS	B314	TORP et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>APMIS</u> 100:713-719 (1992)	
PS	B315	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) © Ashley Publications Ltd.	
PS	B316	TSAI et al., "The Effect of 3,3-Di-Pyridyl Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31:943-947 (1992) ©Pergamon Press	
PS	B317	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)	
PS	B318	TWAMLEY-STEIN et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci. USA</u> 90:7696-7700 (1993)	
PS	B319	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990) copyright Cell Press	
PS	B320	VAISMAN et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990) © The American Society for Biochemistry and Molecular Biology	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		Application Number	
		Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	1614
		Examiner Name	
Sheet 29 of 30	Attorney Docket Number	038602-0994	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B321	VARMA and GUPTA, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989) © The Indian Chemical Society	
PS	B322	VOLLER et al., "Ch. 45 – Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 <sup>nd</sup> edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980); @ American Society for Microbiology	
PS	B323	WAHL et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim.</u> 350 (1926), DATABASE CROSSFIRE, Beilstein Reference No. 2-21-00-00290	
PS	B324	WAHL et al., "Chimie Organique - Sur les iso-indogenides," <u>C.R. Hebd. Seances Acad. Sci.</u> 149:132-134 (1909)	
PS	B325	WAHL, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)	
PS	B326	WAHL, Beilstein Reg. No. 231732, <u>Bull. Soc. Chim. Fr.</u> , pages 1035-1038 (1909)	
PS	B327	WALKER, "Synthesis of a $\alpha$ -(p-Aminophenyl)- and $\alpha$ -(p-Chlorophenyl)- $\beta$ -aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>J. Med. Chem.</u> 8:583-588 (1965)	
PS	B328	WALKER et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-( $\beta$ -Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-637 (1965)	
PS	B329	WARRI et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-I Human Breast Cancer Cells <u>In Vitro</u> and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991) © Wiley-Leiss, Inc.	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		Application Number	
		Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	1614
		Examiner Name	
Sheet	30	of	30
		Attorney Docket Number	038602-0994

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PS	B330	WEIDNER et al., "Tumor Angiogenesis and Metastasis -- Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991) © Massachusetts Medical Society	
PS	B331	WINKELMANN et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," <u>Arzneim.-Forsch./Drug Res.</u> 27:2251-2263 (1977)	
PS	B332	WRIGHT et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>J. Am. Chem. Soc.</u> 78:221-224 (1956)	
PS	B333	WRIGHT et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)	
PS	B334	YOUNG and BABBITT, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon-Paste Electrode in Acidic Aqueous-Ethanol Media," <u>J. Org. Chem.</u> 47:1571-1572 (1982) copyright Am. Chem. Soc.	
PS	B335	ZAMAN et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor $\beta$ -Receptor ( $\beta$ -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57:57-64 (1999) ©Elsevier Science Inc.	
PS	B336	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-234 (1996) ©The American Society for Pharmacology and Experimental Pharmaceutics	
PS	B337	ZHUNGIETU et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Chemical Abstracts</u> , Vol. 78, abstract no. 111201 (1990)	

Examiner Signature	Phyllis Spivack	Date Considered	1/23/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.